Exhibit 99.1 Xencor Reports Third Quarter 2024 Financial Results PASADENA, Calif-- Nov. 6, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. "In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engage ...

Shares of Xencor (XNCR) have gained 7.9% over the past four weeks to close the last trading session at $21.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.33 indicates a potential upside of 68.2%.The average comprises 12 short-term price targets ranging from a low of $20 to a high of $60, with a standard deviation of $11.22. While the lowest estimate indicates a decline ...

Core Viewpoint - Xencor (XNCR) shares have shown a modest gain of 0.4% over the past month, closing at $21.13, with analysts suggesting a potential upside of 67.2% based on a mean price target of $35.33 [1] Price Targets and Analyst Consensus - The average price target for XNCR is derived from 12 short-term estimates, ranging from a low of $20 to a high of $60, with a standard deviation of $11.22, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 5.4%, while the highest indicates an upside of 184%, highlighting the range of opinions among analysts [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Potential Upside - Analysts have shown increasing optimism about XNCR's earnings prospects, as evidenced by a trend of higher EPS estimates, which correlates with potential stock price increases [9] - Over the past 30 days, three earnings estimates have been revised upward, leading to a 1.4% increase in the Zacks Consensus Estimate for the current year [10] - XNCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [11]

tomazl Xencor (NASDAQ:XNCR) is an important biotech to keep an eye on, because it has a lot of upcoming catalysts within a 1-year period for investors to look forward to. One of which would be its lead program using vudalimab, which is an anti-PD-1 and anti-CTLA-4 inhibitor in development for the treatment of patients with metastatic castration-resistant prostate cancer in an ongoing phase 2 study. It is expected that monotherapy and combination dose cohorts' data targeting this specific patient population ...

Xencor (XNCR) shares rallied 10.5% in the last trading session to close at $21.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.8% gain over the past four weeks. This jump in share price came after the company announced that it was floating a secondary issue of common stock, along with pre-funded warrants, to raise nearly $175 million in gross proceeds. Management intends to issue more than 6.6 million ...

Shares of Xencor (XNCR) gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs. Xencor Shares Favorable Updates on Oncology Pipeline The company announced favorable initial results from two early-stage oncology programs. Initial data from an ongoing phase I study showed signs of anti-tumor activity for its investigational ENPP3 x CD3 bispecific antibody XmAb819 in patients with clear cell ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------|-------------------------------- ...

Exhibit 99.1 Xencor Reports Second Quarter 2024 Financial Results PASADENA, Calif.--Aug. 5, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2024 and provided a review of recent business updates and internal clinical-stage programs. "Xencor's clinical focus is developing high-potential, first-in-class bispecific T-cell en ...

Financial Performance - Revenues for Q1 2024 were $12.8 million, a decrease of 32.4% compared to $19.0 million in Q1 2023[7] - Net loss for Q1 2024 was $68.0 million, or $(1.11) per share, compared to a net loss of $60.8 million, or $(1.02) per share, in Q1 2023[11] - Total operating expenses for Q1 2024 were $70.7 million, compared to $79.7 million in Q1 2023, reflecting a decrease of 11.3%[20] Research and Development - Research and development expenses for Q1 2024 were $56.9 million, down 13.2% from $65.6 million in Q1 2023[8] - The first patient was dosed in the Phase 1 study of XmAb541, targeting CLDN6-positive tumors, including advanced ovarian cancer[4] - A single dose of an investigational antibody with Xtend™ showed up to 77% effectiveness in preventing malaria in children[4] Cash and Assets - Cash, cash equivalents, and marketable debt securities totaled $646.7 million as of March 31, 2024, down from $697.4 million on December 31, 2023[6] - Total assets as of March 31, 2024, were $884.3 million, down from $952.7 million on December 31, 2023[18] - Xencor expects to end 2024 with between $475 million and $525 million in cash and equivalents, funding operations into 2027[5] Product Approvals - Ultomiris, incorporating Xencor's Xtend™ technology, was approved in the U.S. for treating adults with NMOSD[4]

Clinical Development - The company is advancing a broad portfolio of clinical-stage XmAb® drug candidates, focusing on engineered antibody therapeutics for cancer and serious diseases [121]. - Five wholly-owned or co-development candidates are currently enrolling in Phase 1 or Phase 2 studies targeting various cancers and autoimmune diseases [124]. - Vudalimab, a bispecific antibody, is being evaluated in a Phase 2 study for metastatic castration-resistant prostate cancer (mCRPC) and has shown encouraging clinical activity [126]. - XmAb819, targeting ENPP3 and CD3, is in a Phase 1 study for advanced clear cell renal cell carcinoma (RCC) [128]. Financial Performance - Total revenues for the three months ended March 31, 2024, were $12.8 million, a decrease of $6.2 million (approximately 32.6%) compared to $19.0 million in the same period of 2023 [149]. - The company has not generated any revenues from its own product sales and continues to incur significant research and development expenses [146]. - The company earned $2.9 million in estimated non-cash royalties from MorphoSys for the three months ended March 31, 2024 [142]. - Net loss attributable to Xencor, Inc. for the three months ended March 31, 2024, was $68.0 million, an increase of $7.2 million (approximately 11.9%) compared to a net loss of $60.8 million in 2023 [149]. - Cash used in operating activities increased to $55.3 million for the three months ended March 31, 2024, compared to $30.6 million in 2023, reflecting a change of $24.6 million [158]. - Other expense, net for the three months ended March 31, 2024, was $10.8 million, primarily due to an impairment charge on equity investments [156]. - General and administrative expenses decreased by $0.4 million (approximately 2.8%) to $13.8 million for the three months ended March 31, 2024, compared to $14.2 million in 2023 [155]. Cash Position - As of March 31, 2024, the company had $646.7 million in cash, cash equivalents, restricted cash, and marketable debt securities, down from $697.4 million as of December 31, 2023 [162]. - The existing cash and marketable securities are expected to fund operating expenses into 2027, based on current operating plans [164]. Research and Development - Research and development expenses decreased by $8.7 million (approximately 13.2%) to $56.9 million for the three months ended March 31, 2024, down from $65.6 million in 2023 [154]. - The company expects to continue to increase operating expenses in connection with ongoing clinical and preclinical development of product candidates [163]. Partnerships and Intellectual Property - The company has a partnership with Genentech for efbalropendekin alfa, with potential milestone payments of up to $600 million and tiered royalties on approved sales [134]. - The company has over 1,500 issued and pending patents worldwide to protect its XmAb technology platform and drug candidates [145]. Regulatory Approvals - The FDA approved Monjuvi® (tafasitamab-cxix) under accelerated approval in July 2020 for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma [141]. Future Expectations - The company has not generated any revenue from product sales to date and does not expect to do so until regulatory approval is obtained [163].